An official website of the United States government
Here’s how you know
Official websites use .gov
A .gov website belongs to an official government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
Measurement Reliability in the Early States of Biomarker Development
Published
Author(s)
Walter S. Liggett Jr, Peter E. Barker, J Semmes
Abstract
Analytical instruments with functional responses such as SELDI-TOF mass spectra offer a basis for biomarker development. This paper describes an approach to improving measurement reliability, that is, to improving the consistency of the instrument response, through assessment of sources of variation. The approach is suitable for instruments with functional responses and can therefore be applied even if clinical interpretation of the response has not yet been fully specified. The approach involves an experiment in which measurement of a reference material is replicated with a source of variation sometimes held fixed and sometimes not. The experimental results are interpreted by means of functional principal components analysis. In our illustration, the functional responses are SELDI-TOF mass spectra, and the source of variation is the difference between protein biochips. Among other things, the experiment shows that the measurement-to-measurement deviations in the heights of spectral peaks have complicated statistical dependencies. The chip-to-chip variation contributes to these deviations but not in an overwhelming way. The paper concludes with a discussion of the need for addition of metrological studies such as the one presented to the case-control studies usually envisioned in biomarker development.
Citation
Disease Markers
Pub Type
Journals
Keywords
functional data analysis, guage R & R, mass spectrum, measurement probability, proteomics, statistics
Citation
Liggett Jr, W.
, Barker, P.
and Semmes, J.
(2008),
Measurement Reliability in the Early States of Biomarker Development, Disease Markers
(Accessed December 9, 2024)